Black Rock Inc. Ocuphire Pharma, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 106,935 shares of OCUP stock, worth $104,796. This represents 0.0% of its overall portfolio holdings.

Number of Shares

106,935

Previous 96,714 10.57%

Holding current value

$104,796

Previous $194,000 15.98%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.51 - $2.23 $15,433 - $22,792	10,221 Added 10.57%	106,935 $163,000
Q1 2024 May 10, 2024	BUY	$1.89 - $3.27 $4,522 - $7,825	2,393 Added 2.54%	96,714 $194,000
Q4 2023 Feb 13, 2024	BUY	$2.59 - $3.64 $2,683 - $3,771	1,036 Added 1.11%	94,321 $283,000
Q3 2023 Nov 13, 2023	BUY	$3.35 - $4.33 $126,918 - $164,046	37,886 Added 68.39%	93,285 $312,000
Q2 2023 Aug 11, 2023	BUY	$3.63 - $6.38 $11,608 - $20,403	3,198 Added 6.13%	55,399 $240,000
Q1 2023 May 12, 2023	SELL	$3.01 - $3.85 $58,698 - $75,078	-19,501 Reduced 27.2%	52,201 $195,000
Q4 2022 Feb 13, 2023	BUY	$2.04 - $3.53 $10,169 - $17,597	4,985 Added 7.47%	71,702 $253,000
Q3 2022 Nov 14, 2022	SELL	$1.82 - $2.79 $8,102 - $12,421	-4,452 Reduced 6.26%	66,717 $135,000
Q2 2022 Aug 12, 2022	BUY	$1.8 - $3.25 $66,425 - $119,934	36,903 Added 107.7%	71,169 $136,000
Q1 2022 May 12, 2022	SELL	$2.75 - $4.39 $3,687 - $5,886	-1,341 Reduced 3.77%	34,266 $112,000
Q4 2021 Feb 10, 2022	BUY	$3.4 - $5.19 $5,759 - $8,791	1,694 Added 5.0%	35,607 $133,000
Q3 2021 Nov 09, 2021	SELL	$3.84 - $5.38 $1,973 - $2,765	-514 Reduced 1.49%	33,913 $175,000
Q2 2021 Aug 11, 2021	BUY	$4.24 - $6.57 $145,970 - $226,185	34,427 New	34,427 $181,000

Others Institutions Holding OCUP

# of Institutions

Shares Held

17.2M

Call Options Held

19K

Put Options Held

View Full List

About Ocuphire Pharma, Inc.

Ticker OCUP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,579,800
Market Cap $20.2M
Description
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...

More about OCUP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account